Translated automatically – community improvements welcome.
Rivastigmine
Rivastigmine is a reversible inhibitor of acetylcholinesterase and butyrylcholinesterase, used for the treatment of dementia in Alzheimer's disease and Parkinson's disease. It increases the availability of acetylcholine in the brain, which may support cognitive functions. The substance is administered orally or transdermally and can cause side effects such as nausea and vomiting. Rivastigmine is not a psychoactive stimulant or sedative, but a specific therapeutic agent for improving cognitive symptoms.
Mechanism of Action
- Acetylcholinesterase inhibitor
Names / Identifiers
IUPAC: Rivastigmine
Mechanism of Action
Rivastigmin hemmt das Enzym Acetylcholinesterase, was zu einer erhöhten Verfügbarkeit von Acetylcholin im synaptischen Spalt führt und somit die cholinerge Transmission verbessert.
Effects
Effects described from scientific sources. Individual experiences vary.
Dosage
Individual sensitivity varies. Not a dosage recommendation.
Duration
Risks & Warnings
Warnings
- Pregnancy
- Liver diseases
Known Risks
- medium
- Mögliche Nebenwirkungen umfassen Übelkeit, Durchfall und Schwindel.
Safer Use
- Start at a low dose.
- Consider regular medical monitoring.
Harm reduction tips do not replace medical advice.
Known Interactions
- Anticholinergics
- Beta-blockers
This list is not exhaustive. Interactions can have unpredictable effects.
Legal Status
Not legal advice. Status may change.